---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-020636"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2022-10-31T23:59:59+00:00"
generated_at: "2026-06-22T21:40:25.460635+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Corbus Pharmaceuticals amends loan agreement, defers principal payments, adjusts conversion prices on $2M of debt

## Summary
- Principal repayments deferred from Sept 2022 to Sept 2023; if Co. raises ≥$30M, extended to March 2024.
- Conversion price on $875K debt lowered to $0.15/share, $1.125M to $0.2625/share (from $9.40).
- Company paid $100K at amendment and will pay $400K at loan maturity.
- Lenders refunded Sept & Oct 2022 principal payments already made.

## SEC filing metadata
- accession: 0000950170-22-020636
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2022-10-31T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017022020636/0000950170-22-020636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017022020636/crbp-20221025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-020636
- JSON: https://secwatch.observer/filing/0000950170-22-020636.json
- Plain text: https://secwatch.observer/filing/0000950170-22-020636.txt

## Key facts
- Material Agreements
  Corbus Pharmaceuticals Holdings, Inc. amended Amended Loan Agreement with K2 HealthVentures LLC, as administrative agent, and the lenders party thereto (effective 2022-10-25).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: K2 HealthVentures LLC, as administrative agent, and the lenders party thereto
  - Effective: 2022-10-25
  source text: On October 25, 2022, Corbus Pharmaceuticals Holdings, Inc. (the “ Company ”) entered into an amendment to the Loan and Security Agreement (the “ Loan Agreement ” and the amendment, the “ Amended Loan Agreement ”), dated as of July 28, 2020, with its subsidiary, Corbus Pharmaceuticals, Inc. as borrower, the Company as guarantor, each lender party thereto (the “ Lenders ”), K2 HealthVentures LLC, as administrative agent for the Lenders, and Ankura Trust Company, LLC, as collateral agent for the Lenders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017022020636/0000950170-22-020636-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.